US Patent

US8653092 — Tetrahydro-pyrido-pyrimidine derivatives

Composition of Matter · Assigned to Novartis AG · Expires 2032-02-19 · 6y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel tetrahydro-pyrido-pyrimidine derivatives suitable for treating disorders or diseases mediated by PI3K enzymes.

USPTO Abstract

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R 1 , R 2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Drugs covered by this patent

Patent Metadata

Patent number
US8653092
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-02-19
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.